Therefore, an active vaccination targeted against circulating PCSK9 if given in early adulthood before developing mature atherosclerotic lesions has the potential to decrease lifetime exposure to plasma LDL-C and may consequently result in potentially strong reductions in the lifetime risk of ASCVD events. Here, PCSK9 is linked to atherosclerosis.